Starting Sunday, March 29th, 2020 beginning at 8:00 AM EDT, and ending on Sunday, March 29th, 2020 beginning at 12:30 AM EDT. During this time there will be no access to the EDC/Rave system. Please share this notification to the personnel who will be affected by this within your organization. Maintenance Start: Sunday, March 29th, 2020 at 8:00 AM EDT. Maintenance End: Sunday, March 29th, 2020 at 12:30 AM EDT.
We are sorry for any inconvenience this may cause.
CCTG and its scope of research has been deemed an essential service by Queen’s University and we continue to be operational for our sites and trial patients. Given the critical nature of our research, we continue to monitor our activities and how trial adjustments can be made to ensure that patients can be managed on protocols.
The CCTG Operations and Statistics Centre has successfully completed the transition to a remote work environment with a small number of support staff in the offices.
Published: March 20, 2020
Category: Office of the Director
As the COVID-19 situation continues to evolve, CCTG is closely monitoring the situation in consultation with our network of investigators and trial staff. The CCTG Operations and Statistical Centre remains operational and has full capabilities to support trial develop and oversight of the current portfolio.For the safety of our community we have completed a transition to remote work for our staff.
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19). After careful consideration and evaluation of available information at this time, and out of an abundance of caution for the entire network, the CCTG Annual Spring Meeting for 2020 is cancelled.
CCTG is actively monitoring the continuing developments pertaining to the coronavirus (COVID-19) . This includes reviewing reliable sources of information nationally and internationally as well as tracking travel restrictions. We are evaluating risks to patient safety, trial conduct and integrity, as well as critical meetings and engagement activities across the network. Safety and security are our top priorities as we review the situation.
The purpose of this study was to find the highest dose of durvalumab or of durvalumab with tremelimumab that can be tolerated without causing very severe side effects when receiving standard chemotherapy and to see what effects the study drugs has on this type of cancer.
Trial closures for BR16 (NCT00008385) trial: Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage 1 Non-Small Cell Lung Cancer and IND222 ( NCT02619864) A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme.
Published: February 19, 2020
Category: Group updates
Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply.